NIH Awards $420,000 to ACRI, UAMS Researcher to Study Chlamydia, Potentially Inform Therapies & Vaccine Development



NIH Awards $420,000 to ACRI, UAMS Researcher to Study Chlamydia, Potentially Inform Therapies & Vaccine Development

Laxmi Yeruva, PhD

LITTLE ROCK - Research to better understand chlamydia, potentially informing the development of a vaccine for the infection, is underway at Arkansas Children's Research Institute (ACRI) and the University of Arkansas for Medical Sciences (UAMS) after the National Institutes of Health (NIH) awarded the project $420,000.

The National Institute of Allergy and Infectious Diseases, part of NIH, is funding the work of Laxmi Yeruva, PhD, an investigator at ACRI and an associate professor of Pediatrics in the UAMS College of Medicine. She and her team will use the two-year award to examine interactions between chlamydia and proteins released by cells during infection.

They believe building a better understanding of how these proteins affect inflammation and tissue damage during infection can lead to novel therapies, possibly even helping vaccine development.

Dr. Yeruva's research has been supported, in part, by funds from the Arkansas Biosciences Institute, the major research component of the Tobacco Settlement Proceeds Act of 2000.